SR604, developed by Shanghai RAAS Blood Products Co., Ltd., is positioned to address the unmet medical need in the treatment of von Willebrand disease (VWD), a prevalent bleeding disorder. The market for VWD treatments is expanding, with increasing awareness and diagnosis leading to a growing patient population. The competitive landscape includes existing therapies such as DDAVP and plasma-derived products, but SR604's unique pharmacokinetic and pharmacodynamic profile may offer advantages in terms of dosing frequency and efficacy. Successful trial outcomes could facilitate market entry and establish SR604 as a preferred treatment option, potentially capturing significant market share. Diligence should focus on the robustness of clinical data, regulatory pathways, and potential reimbursement scenarios.